Foley Hoag Outlines Nasdaq, NYSE Listing Path Post-Schedule III Move

Exchange Listing Requirements Unchanged by Rescheduling Alone

Schedule III rescheduling doesn't automatically grant cannabis operators access to Nasdaq or NYSE listings; companies must still satisfy exchange governance, financial, and disclosure standards identical to those required of non-cannabis issuers. Foley Hoag's memo notes that both exchanges maintain independent director thresholds, audit committee composition rules under SOX Section 301, and minimum market-cap or bid-price requirements that cannabis MSOs currently trading on the CSE or OTCQX haven't uniformly met.

Rescheduling removes the federal Schedule I barrier. That barrier previously made U.S. exchanges unwilling to list cannabis operators. But exchange listing standards themselves remain unchanged. Companies must demonstrate two to three years of audited financials under U.S. GAAP, maintain a majority-independent board, and satisfy minimum public float and shareholder count thresholds.

280E Relief Accelerates Profitability, Strengthens Listing Case

Elimination of IRC Section 280E tax disallowance will materially improve EBITDA and net income for profitable operators, making minimum earnings thresholds easier to satisfy. According to the guidance, Nasdaq's $550,000 pre-tax income standard and NYSE's $10 million aggregate pre-tax income over three years become achievable for mid-tier MSOs once ordinary business deductions are restored.

The bull case for immediate uplisting hinges on whether operators can close the governance and audit gaps within six to nine months of final rescheduling, positioning them for exchange approval by late 2026 or early 2027.

Companies currently reporting under IFRS on Canadian exchanges will need to restate or reconcile financials to U.S. GAAP. That process typically requires one to two audit cycles, Foley Hoag notes.

Board and Audit Committee Gaps Present Near-Term Hurdle

Many cannabis operators lack the majority-independent boards and fully independent audit committees required by Nasdaq Rule 5605 and NYSE Rule 303A. Audit committee financial expertise and independence represent the most common deficiency among CSE-listed MSOs, several of which maintain founder-controlled boards with fewer than three independent directors.

Foley Hoag recommends that management teams begin director searches immediately, targeting candidates with public-company audit committee experience and no material relationships to the issuer. Director onboarding, committee charter amendments, and exchange pre-clearance can extend timelines by three to six months, the firm warns.

Timing and Strategic Considerations for Uplisting

The earliest realistic uplisting window opens six to twelve months after DEA publishes the final rescheduling rule, assuming operators execute governance and financial remediation in parallel. Foley Hoag advises clients to file confidential draft registration statements with the SEC under the JOBS Act while rescheduling is pending, allowing the SEC to begin its review before the final rule takes effect.

Early movers may face higher scrutiny from exchange listing committees, while later filers benefit from established precedent. For operators with significant institutional ownership or debt covenants tied to exchange listing, the guidance suggests prioritizing speed. Smaller operators may reduce execution risk by waiting for peer precedent.

For full background on this story, see the CannIntel topic hub on Cannabis U.S. Exchange Listings.